Physician profile
Pradeep K Manudhane
NPI 1316991599
$1,516,409.92
in general payments reported to CMS, 2019-2025
30 companies · $323K in 2025
The $323K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $81K · 2021: $170K · 2022: $236K · 2023: $271K · 2024: $227K · 2025: $323K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $631K · Consulting Fee: $86K · Travel and Lodging: $54K · Honoraria: $30K · Food and Beverage: $21K · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $630,663.28 |
| Consulting Fee | $85,698.00 |
| Travel and Lodging | $53,799.68 |
| Honoraria | $29,975.00 |
| Food and Beverage | $20,598.03 |
| Education | $209.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $314,380.06 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $313,106.28 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $153,014.42 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $151,145.46 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136,236.06 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $132,346.11 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $86,936.72 | 2024-2025 | Cobenfy |
| Allergan, INC. | $78,293.15 | 2019-2021 | |
| Axsome Therapeutics, INC. | $73,617.07 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $34,680.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19,578.50 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13,994.82 | 2023-2024 | Quviviq |
| Eisai INC. | $7,161.85 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $655.15 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $215.26 | 2019-2024 | Invega, Invega Sustenna, Invega Trinza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $212.16 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $184.86 | 2019-2024 | Rexulti, Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $113.03 | 2019-2022 | |
| Noven Therapeutics, LLC | $104.98 | 2021-2022 | |
| Indivior INC. | $85.14 | 2020-2024 | Sublocade |
| Neuronetics, INC. | $71.03 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $59.68 | 2019-2022 | |
| Almatica Pharma LLC | $58.48 | 2022-2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $44.16 | 2021 | |
| Corium, LLC | $39.61 | 2021-2023 | Azstarys |
| Shire North American Group INC | $34.37 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $17.08 | 2019 | |
| Orexo US, INC. | $12.01 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.78 | 2019 | |
| Validus Pharmaceuticals LLC | $0.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Manudhane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.